Parameters influencing antigen-specific immunotherapy for type 1 diabetes.
Type 1 diabetes (T1D) is a T cell-mediated autoimmune disease in which the insulin producing beta cells are destroyed. Antigen-based immunotherapy provides an approach to selectively tolerize pathogenic beta cell-specific T cells, while leaving the remainder of the immune system intact. In this chapter, we discuss our group's experience in defining the parameters that impact the efficacy of beta cell antigen "vaccination" for the prevention and treatment of T1D.
Department of Microbiology, University of North Carolina at Chapel Hill, Mary Ellen Jones Bldg., Room 635, Campus Box 7290, Chapel Hill, NC 27599-7290, USA.
Bo
B
Wang
Roland
R
Tisch
D000818:Animals; D001324:Autoantigens / Q000276:immunology* / Q000627:therapeutic use*; D015551:Autoimmunity / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology / Q000378:metabolism; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology / Q000378:metabolism / Q000628:therapy*; D005260:Female; D005968:Glutamate Decarboxylase / Q000276:immunology; D007165:Immunosuppression Therapy; D007167:Immunotherapy; D007328:Insulin / Q000276:immunology; D007515:Islets of Langerhans / Q000276:immunology*; D051379:Mice; D016688:Mice, Inbred NOD; D010446:Peptide Fragments / Q000276:immunology; D016176:T-Lymphocyte Subsets / Q000276:immunology* / Q000378:metabolism; D050378:T-Lymphocytes, Regulatory / Q000276:immunology / Q000378:metabolism; D014611:Vaccination
D001324:Autoantigens; D007328:Insulin; D010446:Peptide Fragments; C439756:GAD65 (217-236); D005968:Glutamate Decarboxylase